Mimetogen Pharmaceuticals completes its equity financing

Mimetogen Pharmaceuticals Inc. ("Mimetogen"), a privately held drug development company announced today that it has successfully completed an equity financing, co-led by Boston-based VIMAC Milestone Medica Fund and Montréal-based iNovia Capital. The Company has also completed discussions with the FDA concerning both pre-clinical and clinical development of its lead compound to treat dry eye syndrome.

Mimetogen’s lead drug candidate for keratoconjunctivitis sicca (dry eye syndrome), MIM-D3, is a small molecule neurotrophin mimetic acting as a potent mucin secretagogue. The company first reported pre-clinical efficacy data at ARVO, Fort Lauderdale, in May 2009 and subsequently held a pre-IND meeting with the FDA prior to commencing toxicology and safety pharmacology studies.

The equity investment from iNovia and VIMAC will fund development activities for MIM-D3 up to and including the completion of both Phase I safety and tolerability and Phase II proof of concept studies in humans. “The strong preclinical efficacy and toxicology data combined with a well defined clinical development plan has made for an extremely compelling investment opportunity”, noted Garth Cumberlidge, Chief Executive Officer at Mimetogen. “Dry eye is a large and growing market which is ripe for innovative and effective drugs. We are confident that the combination of our strong data coupled with industry interest in this sector creates a unique business opportunity”. In addition to dry eye, Mimetogen is working on a pipeline of drugs in retinitis pigmentosa and dry macular degeneration.

Mimetogen will be discussing this and its other development plans on Thursday, October 8th at 2 pm at the annual BioContact Symposium in Québec City, Canada.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New inhaled treatment may lead to self-administered therapy for COVID-19